|
Metabolic Syndrome X
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated blood viscosity decreases the perfusion of skeletal muscle, leading to myocyte expression of the myokine IL-6, decreased glucose uptake, insulin resistance, hyperglycemia, and metabolic syndrome.
|
29435395 |
2017 |
|
Metabolic Syndrome X
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Total ROS, inflammatory parameters and adhesion molecules were enhanced in the presence of MetS (p<0.05), and the PCOS+MetS group showed higher levels of IL-6 and ICAM-1 than controls (p<0.05).
|
28521868 |
2017 |
|
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
Urinary d<sub>6</sub>-α-CEHC 24-h concentrations were associated with the plasma AUC<sub>0-24 h</sub> of d<sub>6</sub>-α-T (<i>r</i> = 0.53, <i>P</i> = 0.02) and d<sub>6</sub>-α-CEHC (<i>r</i> = 0.72, <i>P</i> = 0.0003), and with urinary d<sub>6</sub>-α-CMBHC (<i>r</i> = 0.88, <i>P</i> < 0.0001), and inversely with the plasma inflammation biomarkers C-reactive protein (<i>r</i> = -0.70, <i>P</i> = 0.0006), interleukin-10 (<i>r</i> = -0.59, <i>P</i> = 0.007), and interleukin-6 (<i>r</i> = -0.54, <i>P</i> = 0.01).<b>Conclusion:</b> Urinary α-CEHC and α-CMBHC are useful biomarkers to noninvasively assess α-tocopherol adequacy, especially in populations with MetS-associated hepatic dysfunction that likely impairs α-tocopherol trafficking.
|
28077381 |
2017 |
|
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anthropometric measures were correlated with the components of MetS (triglycerides, glucose, blood pressure, and high-density lipoprotein cholesterol) as well as inflammation markers (interleukin-6 and tumor necrosis factor-alpha , C-reactive protein, and ceruloplasmin).
|
29037330 |
2017 |
|
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
Psoriatic patients with MS showed a much less reduction of IL-17 and IL-6 before and after 10 sections of NB-UVB treatment respectively than patients without MS (P < .05).Psoriatic patients with MS have poorer improvement in comparison those without MS using NB-UVB treatment.
|
29390261 |
2017 |
|
Metabolic Syndrome X
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, other diagnostic criteria of MS (hypertension and/or dyslipidemia) or elevated IL-6 levels does not cause further increase in GV.
|
28163257 |
2017 |
|
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-6 remains an independent predictive biomarker for LVDD in MetS patients, underlining the importance of IF in the evolution of MetS to subclinical cardiac damage.
|
29099655 |
2017 |
|
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
The significantly higher distribution of risk polymorphisms in PSEN1 and APOE-ε4 is characteristic of a representative number of patients with Alzheimer's disease; whereas polymorphisms in ACE, AGT(235), and IL6(573), are most probably related with the high number of patients with metabolic syndrome or cerebrovascular damage.
|
29081698 |
2017 |
|
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
Strong associations with arrhythmia were observed for IL-6 (median 3.90 vs 1.89 pg/mL, p<0.00001) and CRP concentration (6.32 vs 1.47 mg/L, p=0.00009), while MS was associated most strongly with IL-6.
|
26864064 |
2016 |
|
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The C allele at the -174 locus of IL-6 gene is independently associated with the occurrence of metabolic syndrome, emphasizing the importance of inflammatory genetic background in the pathogenesis of visceral obesity and related cardiovascular burden.
|
25815341 |
2015 |
|
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
All PPAR SNPs were not associated with obesity and Met-S in the suburban population of Kampar, Malaysia, where only PPARα V162 and PPARγ2 T161 alleles were associated with plasma IL-6 and HOMA-IR, respectively.
|
26673968 |
2015 |
|
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
Low COX4I1 was associated with type 2 diabetes in obese patients, adjusting for age, gender, smoking, interleukin-6 and high-sensitivity C-reactive protein, all related to metabolic syndrome (MetS; odds ratio: 6.1, 95% confidence interval: 2.3-16).
|
25869607 |
2015 |
|
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
TLR-2 and TLR-4 expressions were associated with increased pro-inflammatory cytokines, IL-6 and TNF-α, with no association with biomarkers of MetS.
|
25329057 |
2014 |
|
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of the study was to estimate the influence of interactions between peroxisome proliferator-activated receptor γ (PPARγ) and target genes lipoprotein lipase (LPL), interleukin 6 (IL6), angiotensin converting enzyme (ACE), and angiotensin II type 1 receptor (AT1R) on metabolic syndrome (MetSy) and its traits.
|
24200052 |
2014 |
|
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum MCP-1 (P = 0·02), eotaxin-1 (P = 0·02) and MIP-1β (P = 0·03), CRP (P < 0·001) and IL-6 (P = 0·006) were significantly increased in metabolic syndrome in comparison with lean controls.
|
23170936 |
2013 |
|
Metabolic Syndrome X
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The Overwt-MetSyn group demonstrated a significant elevation in expression of TLR2, TLR4, tumour necrosis factor-a (TNF a) and interleukin-6 (IL6) in peripheral monocytes, and increased circulating levels of TNF a and IL6 when compared with the Overwt-Healthy group.
|
22991262 |
2013 |
|
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
Manipulation of iron status with ferric ammonium citrate and hepcidin-25 induced monocyte chemoattractant protein (MCP)-1 and interleukin-6 in human differentiating monocytes of patients with hyperferritinemia associated with the metabolic syndrome (n=11), but not in subjects with hemochromatosis or HFE mutations impairing iron accumulation (n=15), and the degree of induction correlated with the presence of carotid plaques, detected by echocolor-Doppler.
|
21183736 |
2011 |
|
Metabolic Syndrome X
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Plasma IL-6, PAI-1 and TNFα levels were higher in MS. P2X(7)R mRNA and protein, identified in both VAT and SAT, were more abundant in MS than in CTL.
|
21978920 |
2011 |
|
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.
|
21749608 |
2011 |
|
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Study suggests that IL-6 G-174C gene is one among the susceptibility loci for metabolic syndrome in North Indian women.
|
21177727 |
2011 |
|
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Single-nucleotide polymorphisms in the genes encoding for IL-6 (g.-634G>C; c.174G>C), TNFα (g.-308G>A), methylenetetrahydrofolate reductase (MTHFR) (c.677C>T), APOC3 (c.3175C>G), and APOA5 (g.-1131T>C) have been implicated in the processes of inflammation and energy intake that take place in the development of MetS manifestations.
|
21473680 |
2011 |
|
Metabolic Syndrome X
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We have investigated the expression of PAI-1, IL-6 and IL-18 in subcutaneous adipose tissue (AT) of subjects with (n = 22) and without (n = 36) MetS.
|
21842238 |
2011 |
|
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
LTA, TNF-alpha, and IL-6 genotype interactions increased MetS risk, which was further exacerbated by a low plasma polyunsaturated to saturated fat exposure, indicating important modulation of genetic risk by dietary fat exposure.
|
20080841 |
2010 |
|
Metabolic Syndrome X
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, patients suffering from the metabolic syndrome with high levels of sCD40L also displayed high levels of IL-6, in line with the concept that CD40L may induce the expression of inflammatory cytokines in vivo in this population.
|
20174757 |
2010 |
|
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interleukin-6 receptor gene polymorphism modulates interleukin-6 levels and the metabolic syndrome: GBCS-CVD.
|
20186139 |
2010 |